Log In
Print
BCIQ
Print
Print this Print this
 

GZ402663, sFLT-01

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionAnti-VEGF chimeric molecules delivered by AAV vectors
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPhase I
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat age-related macular degeneration (AMD)
Regulatory Designation
Partner Applied Genetic Technologies Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$65.0M

$20.0M

$45.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today